Physician profile
Denise E Davis
NPI 1639278534
$5,709.37
in general payments reported to CMS, 2019-2025
23 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $880 · 2021: $599 · 2022: $928 · 2023: $185 · 2024: $1,094 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,465.92 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $895.96 | 2019-2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $625.30 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $381.49 | 2019-2022 | |
| Lundbeck LLC | $353.89 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $327.93 | 2019-2021 | |
| Abbvie INC. | $234.49 | 2021-2024 | |
| Allergan, INC. | $219.64 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $169.53 | 2019-2021 | |
| Corium, LLC | $138.82 | 2024 | Azstarys |
| Shire North American Group INC | $127.61 | 2019 | |
| Axsome Therapeutics, INC. | $123.75 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.54 | 2020-2024 | Caplyta |
| Orexo US, INC. | $115.49 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $84.33 | 2021-2024 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $84.27 | 2022 | |
| Neos Therapeutics, LP | $69.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $65.66 | 2023 | Quviviq |
| Bausch Health US, LLC | $29.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.35 | 2019 | |
| Eisai INC. | $23.10 | 2020 | |
| Indivior INC. | $18.51 | 2019 | |
| Noven Therapeutics, LLC | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.